Science1 min read

Moderna shares plunge after leak of partial cancer vaccine data

By · Published by Everything Blog

In short

Moderna's stock plummeted by up to 25% after a leak of partial data on its cancer vaccine, despite the full results being positive and expected. The personalized vaccine, Intismeran Autogene, paired with Merck's immunotherapy Keytruda, reduced the risk of recurrence or death in certain melanoma patients by 42% when used in combination with Keytruda alone. The late-stage trial results were set to be presented at the European Society for Medical Oncology conference this weekend.

Key points

  • Moderna's stock plummeted by up to 25% after a leak of partial data on its cancer vaccine…: Moderna's stock plummeted by up to 25% after a leak of partial data on its cancer vaccine, despite the full results being positive and expected.
  • The personalized vaccine, Intismeran Autogene, paired with Merck's immunotherapy Keytruda…: The personalized vaccine, Intismeran Autogene, paired with Merck's immunotherapy Keytruda, reduced the risk of recurrence or death in certain melanoma patients by 42% when used in combination with Keytruda alone.
  • The late-stage trial results were set to be presented at the European Society for Medical…: The late-stage trial results were set to be presented at the European Society for Medical Oncology conference this weekend.

Sources checked by our analysis pipeline: 1

Timon Schneider | SOPA Images | Lightrocket | Getty Images

Moderna shares dropped as much as 25% on Thursday following the leak of partial data on its closely watched cancer vaccine developed with Merck.

The stock fell even though the full data, released later Thursday, appeared positive based on Wall Street expectations ahead of the release. The personalized vaccine, known as intismeran autogene, paired with Merck's immunotherapy Keytruda reduced the risk of recurrence or death in certain melanoma patients by 42% compared to Keytruda alone.

The late-stage trial results were set to be presented at the European Society for Medical Oncology conference this weekend.

This story is developing. Please check back for updates.

Original source: www.cnbc.com

Science